Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 5Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Renal Cell 4Kidney Neoplasms 2Colorectal Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Rituximab 47Cyclophosphamide 45fludarabine 22Filgrastim 21Lenalidomide 18fludarabine phosphate 17Prednisone 16Radiotherapy 15Peripheral Blood Stem Cell Transplantation 15Etoposide 15Vincristine 14Doxorubicin 14Melphalan 13Busulfan 13pembrolizumab 11Tacrolimus 11Methotrexate 10Gemcitabine 10ibrutinib 9Bendamustine Hydrochloride 9Alemtuzumab 9obinutuzumab 8Bortezomib 8Vorinostat 7Mycophenolic Acid 7Granulocyte Colony-Stimulating Factor 7Carboplatin 7Azacitidine 7venetoclax 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma × Interferon-alpha × Clear all
NCT00637117 2017-06-12

Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.

Baylor Research Institute

Phase 1/2 Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡